Funding

PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects. We want to smooth your path to progress. We blend the right funding with the right advice and the right people to give your idea the best chance of success.

New call for proposals: 2025 Antibacterial Therapeutics

We are helping to create and advance an exciting and diverse pipeline of therapeutics aimed at treating bacterial infections with high unmet need. Our third funding round focuses on early-stage, novel, antibacterial therapeutics.

  • Up to £6 million is available to support up to 8 projects, with a maximum of £1 million available per project.
  • Projects are expected to last for up to two years.
  • We welcome applications for projects seeking maximum award and for smaller-scale, innovative or higher-risk projects requiring less funding.
  • Innovators worldwide are eligible to apply, and there is no requirement for a UK-based partner.

Expressions on interest are invited by 23:59 (GMT) on 5 November. An informational webinar will be held on 8 October at 15:00 (BST) – you can register using the link at the bottom of the page.

Array

PACE is not just about grant funding; we offer a truly collaborative approach to project development and delivery. Those who secure funding will benefit from a network of potential project partners as well as receiving advice and guidance from some of the best experts in the field. And we’re there for the long run, so whether you move to the next stage of development or are not successful in securing a grant this time around, you can stay plugged into our community and continue to benefit from our expert ecosystem. 

Seeking projects with the greatest potential

 

We are looking for projects, in Hit-to-Lead or Lead Optimisation phases, seeking to treat Gram-negative bacterial infections associated with the highest burden of AMR, as highlighted by the Lancet studies. Indications in scope are: lower respiratory tract infections (LRTI), blood stream infections (BSI) and complicated urinary tract infections (cUTI). Therapeutics must target one or more drug-resistant priority Gram-negative pathogens: Enterobacteriaceae (prioritising E. coli and K. pneumoniae), A. baumannii and/ or P. aeruginosa 

We are seeking the most innovative and differentiated projects with the potential to address drug-resistant infections where treatment options are limited. Funded projects will be expected to demonstrate strong potential to meet the WHO innovation criteria (a new chemical class; a new target; a new mechanism of action; the absence of cross resistance), focusing on candidates with the greatest likelihood of delivering meaningful clinical benefit.

In summary, projects will be prioritised that are developing solutions aligned with the following product profiles:
Click image to download. 

 

Eligibility

  • Our funding is open to researchers in academia and small and medium enterprises (SMEs) worldwide, including consortia (large pharma partners permitted, but must cover own costs).
  • Applications should have a single lead applicant; however, co-applicants are welcome.
  • There is no requirement for a UK-based partner.

What is in scope:

 

  • Hit-to-Lead and Lead Optimisation phase projects.
  • Any novel targets OR novel chemical classes including but not limited to the following mechanisms; direct-acting and non-direct acting antimicrobials, anti-virulence approaches, immunomodulatory agents, and potentiators.
  • Any modality, including but not limited to small molecules, natural products, peptides, nucleic acid-based, antibodies, proteins, complex/targeted modalities, phage; the therapeutic must have an antimicrobial effect.

What is out of scope:

 

  • Target Identification, screening and Hit Identification. 
  • Projects focussed on late-stage pre-clinical/IND-enabling studies.
  • Clinical Phase R&D.
  • Antibiotics based on iterations of existing therapeutics e.g. β-lactams.
  • Vaccines.
  • Interventions focussed exclusively on mycobacteria (including TB), fungal infections, Gram-positive pathogens or Gram-negative pathogens that fall outside the scope of the call’s Target Product Profiles (TPPs).
  • Therapeutics solely focussed on out-of-scope indications with no potential to pivot (e.g. topical treatments for skin infections).
  • Projects not directly focused on antimicrobial development (e.g. diagnostics, delivery methods, biomarkers, standalone technology or model development).

Application Process

The expression of interest stage is now open for applications. The closing date for submission is 23:59 (GMT) 5 November 2025. Shortlisted applicants will be invited to the full application stage in December 2025. 

Catalyser will be available for all shortlisted applicants to support them in developing their full applications, with an initial workshop to take place in January 2026. Final funding decisions will be communicated in July 2026, with an expectation of project initiation within three months of receipt of the award letter. Key steps in the process are summarised. 

Please note only applicants that have submitted expressions of interest will be eligible for full applications once selected.

Apply Here
shape

Launch Webinar

To support those interested in applying, we will be holding an online webinar followed by a live Q&A at 15:00 (BST) on 8 October 2025. 

Sign Up Here

2024 Diagnostic Innovations Funding Round (Closed)

Our second funding round (launched in September 2024) focused on early-stage diagnostic innovations with the potential to reduce inappropriate antibiotic prescriptions, provide faster results to guide antimicrobial use and clinical decisions and/or catalyse the move to personalised narrow-spectrum treatments.

Learn More

2023 Antibacterials Therapeutics Funding Round (Closed)

Our first funding round (launched in October 2023) focused on early stage, novel antibacterial therapeutics.

Learn More

Frequently Asked Questions

About PACE

What is the PACE Academy?

The Academy is part of PACE’s commitment to providing support as well as funding to PACE portfolio projects. The content of the Academy will be tailored to the cohort of funded projects but is expected to connect innovators with a variety of stakeholders and experts, who will provide tailored support and guidance to help teams progress their assets. For example, this could include support with scientific study design, regulatory strategy or introductions to downstream funders or investors.

What is PACE, is it just about grant funding?

PACE is a collaboration between three leaders in the UK's health innovation and research community. The £30m initiative harnesses the expertise of the partner organisations to not only grant fund projects but also to offer advice and mentorship and to provide access to a collaborative network of potential project partners to enable the best chance of project success - de-risked and investment-ready assets for potential downstream funding (by e.g. CARB-X, corporate and venture investment and other later stage funding and support mechanisms). 

What is the PACE Catalyser?

The Catalyser is part of PACE’s commitment to strengthening the AMR research ecosystem by providing support to applicants that are selected to submit Full Applications following the EOI stage. The support provided will be aimed at helping development of Full Applications and, as part of this, shaping projects with maximum potential to deliver de-risked and investment-ready assets for onward development.

What is the role of the PACE R&D Advisor?

PACE R&D Advisors will actively engage with you and your project team throughout the lifecycle of the project (including helping develop the full application). Support will be tailored to individual project needs (defined at the full application stage). Support may include signposting and making connections across the PACE delivery partner network and beyond as needed; mentorship and advice including but not limited to drug/diagnostic discovery, disease area insight, experimental work package design and support to engage 3rd party delivery partners as needed (e.g. development of a statement of works and acting as the point of contact); facilitating scientific advisory boards and public and patient engagement panels. PACE R&D Advisors will not make funding decisions about your project, but they will be involved in reporting on project progress to the PACE Joint Programme Management Board.

Do you anticipate future funding calls?

We expect further funding calls aligned with our aim to bring together the sector to help innovators with early-stage antimicrobial and diagnostic projects move forward with greater speed and confidence, accelerating the delivery of new innovations to tackle AMR. The exact nature and timings will be determined. 

Delivery Partners and Ecosystem

Can PACE provide access to any other wider enabling capabilities?

As part of PACE support, we are tackling barriers to AMR therapeutic and diagnostic development by connecting global innovators with UK national capabilities to help shape and drive projects forward. One such cross-cutting collaboration established is with the UK Health Security Agency (UKHSA) to enable early evaluation of in vitro antimicrobial activity across the PACE therapeutics portfolio. We are continually assessing the AMR ecosystem to identify additional capabilities that can strengthen delivery of our portfolio of projects and address common gaps within data packages. To find out more about enabling technologies and capabilities, please visit the Partnerships page.

What is the PACE Delivery Partner Network, how do I access it and do I have to use it?

PACE has brought together a network of delivery partners to enable all aspects of outsourced project work across the PACE-funded project portfolio. PACE recognises that not all applicants will have the internal resources and pre-existing relationships required for end-to-end project delivery and, for that reason, wants to be able to facilitate connections and collaborations. Recipients of PACE Project Awards will retain the right to choose whom they work with to deliver their project, including where the Recipient has established relationships with their own delivery partners. PACE R&D Advisors will work closely with Recipients of funding to identify where access to a PACE delivery partner is in the best interests of the project.   

How does my organisation become a PACE delivery partner?

To find out more and apply to join the delivery partner network, please visit the Delivery Partner Network webpage.

Funding Rounds: Eligibility

Can investigators/applicants be on multiple applications?

Yes, if the projects are distinct and unrelated. 

Our project is not in scope. Is there anything PACE might be able to support with?

We would always welcome enquiries and may be able to help or advise. You can contact us and also sign up to receive PACE news. 

If my application is rejected, will I be eligible for future funding calls?

We want to support innovators and would encourage you to apply to other calls; resubmission of the same proposal without addressing feedback would be likely rejected.

Do I need to have the capabilities, tools and facilities to deliver the project in house?

No. However, applicants will need to articulate a clear plan as to what capability, tools or facilities will be accessed to deliver the proposed research plan, either through collaboration with project partners or by outsourcing defined parts of the research plan to Contract Research Organisations (CROs). Any gaps or areas applicants would like support on can be outlined in the respective section of the expression of interest. Applicants that are invited to submit a full application to PACE following expressions of interest will have the opportunity to take part in a Catalyser which will include the opportunity for PACE to facilitate connections with the PACE Delivery Partner Network. Value for money must be demonstrated for outsourced CRO work. 

I’m not based in the UK, can I apply?

Yes, these are global funding calls therefore, you can apply, subject to the eligibility criteria provided on the funding pages. You do not need a UK-based partner to apply.

Are academics eligible to apply?

We welcome applications from academics and SMEs meeting the funding call's eligibility criteria.

How do you define SMEs?

A breakdown of the different organisation sizes is in the below table:

Qualifying Criteria Small Enterprises Medium- Sized Enterprises Large – Sized Enterprises
Turnover Not more than £10.2 million Not more than £36 million Above £36 million
Balance Sheet Total Not more than £5.1 million Not more than £18 million Above £18 million
Number of Employees Not more than 50 Not more than 250 Above 250

Can a consortium apply?

Yes, but a lead applicant from an eligible SME, academic or organisation would need to be listed on the application. Co-applicants will be subject to the same standard PACE T&Cs as the lead applicant.   

What level of experience should a principal investigator have to be considered eligible?

A Principal investigator would typically be a research active member of staff (incl. Postdoctoral researchers) who can demonstrate: experience in the successful management and delivery of (ideally translational) research projects; experience in leading collaborative research projects; and relevant technical expertise.

Funding Rounds: Application Process

Where can I see an overview of the application process?

On the funding pages for each funding round, you can find a graphic depicting the stages and timescales of the application process. 

Where is the link to the application portal to apply for funding?

When a funding call is live, you can access the application portal on the relevant funding page for that call.

Can I save the Expression of Interest as a draft within the submission portal?

Yes, you can, once you have logged in using the Submittable link and filled in the applicant section.

Will the PACE team offer support to applicants for the Expression of Interest stage?

The funding round launch webinar and supporting slides for each funding round provide an overview of PACE, a detailed description of the call scope and application process. During an open funding call, you can complete an enquiry form on the relevant funding page so we can answer your questions. For general enquiries, you can reach out to us via our Contact Us page.

Will feedback be provided on Expressions of Interest?

Yes, you will be informed as to whether your application has been successful soon after a decision has been made, and we will aim to provide brief summary feedback.

Can I add references into my application?

We strongly encourage that key data or material to support the application should be included and references (PMIDs) provided throughout.

Funding Rounds: Review and Award Process

How detailed does the project plan and costings have to be at the EoI stage?

At this stage, we’re looking for a high-level overview of project objectives and key deliverables, as well as an outline of the workstreams and associated milestones. Overall project budget and breakdown by milestones should be provided, however, we will work with successful applicants to refine these in the Full Application stage. 

Who will see my application?

Representatives from managing partners (MDC, IUK and LifeArc) will review your application at the Expression of Interest stage. All partners will abide by PACE confidentiality and Conflict of Interest Policy and procedures. In addition, we may share applications with scientific experts and patient representatives who will also abide by PACE confidentiality and Conflict of Interest Policy and procedures.

When will I hear if my application has been successful, and when might projects start?

Timelines for the whole application process can be found on the funding page for the call you are interested in. The exact start time of the project may vary depending on the nature of the project, applicant timelines and contracts being confirmed for all parties. We anticipate that projects will start within three months of receipt of the Award Letters. 

Funding Rounds: Finances

Are University overheads eligible?

No, overheads are not a permitted cost. Only direct costs will be funded. PACE post award guidance which includes information on permitted costs is available here.

What is the nature of the funding? Is it 100% non-dilutive?

Project funding will be provided as a philanthropic grant. Funding will be non-dilutive, and investigators will own all arising IP generated as set out in our T&Cs.

What expenses are covered? Are salary costs eligible?

Awards shall cover 100% of the direct costs of the Recipient Project, provided such costs are Permitted Expenditure. Permitted Expenditure is expenditure which is reasonably incurred and properly evidenced and is directly related to and necessary for the delivery of the Project, in accordance with the Project Plan and Budget; complies with the Subsidy Law (in the case of a UK enterprise) and is not an expenditure on an Ineligible Cost. Examples of types of permitted expenditure include an appropriate %FTE of staff (Post Docs), plus consumables directly related to funded work, access to specialist equipment/reagents, and Contract Research Organisation work. Details on permitted expenditure can be found in the T&Cs with further post-award funding guidance also available. 

When and how are funds transferred to a company/academic after entry into the portfolio?

Payments will be made quarterly in arrears. Payments will be limited to the current active milestone working towards agreed associated success criteria. 

Innovate-UK, part of UK Research and Innovation, an executive non-departmental public body, is a funder. What does this mean for me with regard to my obligations under subsidy law?

If you are a UK Enterprise (as defined in the Subsidy Control Act 2022) and any part of the award sums provided to you are provided by UKRI-Innovate UK, this portion of the award is a subsidy and is provided under the RDI Streamlined Route. Recipients shall comply with the requirements of the Subsidy Control Act, the Streamlined Route, and any other applicable legislation. 

Funding Rounds: Exploitation of Results and Intellectual Property

Who will own the IP generated in a funded project? Do I need to have patents in place before applying?

IP generated during the course of the Project will usually reside with the funded party(s). The contractual terms of any outsourced work should ensure that the contracting organisation will own arising IP generated under the contract. You should ensure that you have freedom to operate - i.e. you have access to or a reasonable plan to obtain access to the required background IP to commercialise the project outputs. We will review your translational plan and whether you have freedom to operate when we assess your application.